Grant of options

RNS Number : 2859W

C4X Discovery Holdings PLC

26 April 2016

 

26 April 2016

C4X Discovery Holdings plc ("C4XD" or the "Company")

Grant of Options

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, announces that on 8^th December 2015 Clive Dix, Executive Chairman, was granted options over 500,000 ordinary shares of one pence each in the capital of the Company ("Ordinary Shares"). The options have an exercise price of 77p being the average of the mid-market closing price of the Ordinary Shares over the three days prior to 8 December 2015. Subject to Clive Dix meeting certain performance criteria, the options can be exercised at any time between 3 years and 10 years of them being granted.

Following grant of these options, Clive Dix has the following interest in Ordinary Shares:

Total number of Ordinary Shares held	Total number of options over Ordinary Shares
691,250	520,000

--ENDS--

For further information please contact:
C4X Discovery Holdings plc Clive Dix, Executive Chairman	07801 865803
Zeus Capital Dan Bate Dominic Wilson/Phil Walker	0161 393 1973 0203 829 5000
Consilium Strategic Communications Mary-Jane Elliott, Chris Gardner, Matthew Neal, Chris Welsh	0203 709 5700

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.

The Company was founded in 2008 as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically. For additional information please go to: www.c4xdiscovery.com

 

END

 

 

DSHEAFLSAASKEAF